Skip to main content
SpringerLink
Log in

Prognostic value of cyclin B in endometrial endometrioid adenocarcinoma

  • Research Article
  • Published:
Tumor Biology

Abstract

Cyclins are a group of cell cycle regulatory proteins. Cyclin B acts as an activator to cyclin-dependent kinase 1 (CDK1), a protein kinase essential for G2/M phase transition. Deregulation of cyclins has been linked to a number of malignant neoplasms, but the impact on clinicopathological parameters seems to be cancer-specific. Overexpression of cyclin B has been shown to affect survival in some malignant tumors, including breast and esophageal cancer, but its impact on endometrial cancer has not been extensively studied. For this study, 211 endometrial endometrioid adenocarcinoma samples were obtained from patients surgically treated at the Oulu University Hospital. The samples were immunohistochemically stained and analyzed for cyclin B expression. The relationships between cyclin B expression and conventional prognostic factors were analyzed. A discrimination threshold for survival analyses was calculated by utilizing the receiver operator characteristic (ROC) method. Cyclin B expression correlated with grade and advanced stage. Survival analyses showed that cyclin B expression affects cancer-specific survival in univariate analysis. In multivariate analysis, the results were indicative that cyclin B may hold independent prognostic significance, but further studies are required to assess this.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig 1
Fig 2
Fig 3

Similar content being viewed by others

References

  1. Finnish Cancer Registry. Cancer Statistics. 2012. http://www.cancer.fi/syoparekisteri/en/statistics/. Accessed: 9 May 2014.

  2. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, et al. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet. 2006;95 Suppl 1:S105–43.

    Article  Google Scholar 

  3. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynecol Obstet. 2009;105(2):109.

    Article  Google Scholar 

  4. Gadducci A, Cosio S, Genazzani AR. Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer. Crit Rev Oncol Hematol. 2011;80(2):181–92.

    Article  PubMed  Google Scholar 

  5. Harashima H, Dissmeyer N, Schnittger A. Cell cycle control across the eukaryotic kingdom. Trends Cell Biol. 2013;23(7):345–56.

    Article  CAS  PubMed  Google Scholar 

  6. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–66.

    Article  CAS  PubMed  Google Scholar 

  7. Doree M, Hunt T. From Cdc2 to Cdk1: When did the cell cycle kinase join its cyclin partner? J Cell Sci. 2002;115(Pt 12):2461–4.

    CAS  PubMed  Google Scholar 

  8. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res. 2005;11(11):3974–86.

    Article  CAS  PubMed  Google Scholar 

  9. Cooper WA, Kohonen-Corish MR, McCaughan B, Kennedy C, Sutherland RL, Lee CS. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer. Histopathology. 2009;55(1):28–36.

    Article  PubMed  Google Scholar 

  10. Nozoe T, Korenaga D, Kabashima A, Ohga T, Saeki H, Sugimachi K. Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus. Clin Cancer Res. 2002;8(3):817–22.

    CAS  PubMed  Google Scholar 

  11. Takeno S, Noguchi T, Kikuchi R, Uchida Y, Yokoyama S, Muller W. Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinoma. Cancer. 2002;94(11):2874–81.

    Article  CAS  PubMed  Google Scholar 

  12. Aaltonen K, Amini RM, Heikkila P, Aittomaki K, Tamminen A, et al. High cyclin B1 expression is associated with poor survival in breast cancer. Br J Cancer. 2009;100(7):1055–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Nimeus-Malmstrom E, Koliadi A, Ahlin C, Holmqvist M, Holmberg L, et al. Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort. Int J Cancer. 2010;127(4):961–7.

    CAS  PubMed  Google Scholar 

  14. Horree N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP. Progressive derailment of cell cycle regulators in endometrial carcinogenesis. J Clin Pathol. 2008;61(1):36–42.

    Article  CAS  PubMed  Google Scholar 

  15. Milde-Langosch K, Bamberger AM, Goemann C, Rossing E, Rieck G, et al. Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. J Cancer Res Clin Oncol. 2001;127(9):537–44.

    Article  CAS  PubMed  Google Scholar 

  16. Kayaselcuk F, Erkanli S, Bolat F, Seydaoglu G, Kuscu E, Demirhan B. Expression of cyclin H in normal and cancerous endometrium, its correlation with other cyclins, and association with clinicopathologic parameters. Int J Gynecol Cancer. 2006;16(1):402–8.

    Article  CAS  PubMed  Google Scholar 

  17. Rijcken F, van der Zee A, van der Sluis T, Boersma-van Ek W, Kleibeuker J, Hollema H. Cell cycle regulators and apoptosis-associated proteins in relation to proliferative activity and degree of apoptosis in HNPCC versus sporadic endometrial carcinoma. Histopathology. 2006;48(3):275–85.

    Article  CAS  PubMed  Google Scholar 

  18. Shih HC, Shiozawa T, Kato K, Imai T, Miyamoto T, et al. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum Pathol. 2003;34(5):471–8.

    Article  CAS  PubMed  Google Scholar 

  19. Yam CH, Fung TK, Poon RY. Cyclin A in cell cycle control and cancer. Cell Mol Life Sci. 2002;59(8):1317–26.

    Article  CAS  PubMed  Google Scholar 

  20. Xu XL, Chen SZ, Chen W, Zheng WH, Xia XH, et al. The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a meta-analysis. Breast Cancer Res Treat. 2013;139(2):329–39.

    Article  CAS  PubMed  Google Scholar 

  21. Huang LN, Wang DS, Chen YQ, Li W, Hu FD, et al. Meta-analysis for cyclin E in lung cancer survival. Clin Chim Acta. 2012;413(7–8):663–8.

    Article  CAS  PubMed  Google Scholar 

  22. Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009;101(7):452–74.

    Article  PubMed  Google Scholar 

  23. Begnami MD, Fregnani JH, Nonogaki S, Soares FA. Evaluation of cell cycle protein expression in gastric cancer: cyclin B1 expression and its prognostic implication. Hum Pathol. 2010;41(8):1120–7.

    Article  CAS  PubMed  Google Scholar 

  24. Shin JU, Lee CH, Lee KT, Lee KH, Kim KM, et al. Prognostic significance of ATM and cyclin B1 in pancreatic neuroendocrine tumor. Tumor Biol. 2012;33(5):1645–51.

    Article  CAS  Google Scholar 

  25. Santala S, Talvensaari-Mattila A, Soini Y, Honkavuori-Toivola M, Santala M. High expression of cyclin A is associated with poor prognosis in endometrial endometrioid adenocarcinoma. Tumor Biol. 2014;35(6):5395–9.

    Article  CAS  Google Scholar 

  26. Ahmed A, Zamba G, DeGeest K, Lynch CF. The impact of surgery on survival of elderly women with endometrial cancer in the SEER program from 1992–2002. Gynecol Oncol. 2008;111(1):35–40.

    Article  PubMed  Google Scholar 

  27. Benedetti Panici P, Basile S, Salerno MG, Di Donato V, Marchetti C, et al. Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma. Am J Obstet Gynecol. 2014;210(4):363.e1–10.

    Article  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Oulu University Hospital, P.O. Box 24, FI-90029, Oulu, Finland

    Simi Santala, Anne Talvensaari-Mattila & Markku Santala

  2. Department of Pathology, Oulu University Hospital, P.O. Box 24, FI-90029, Oulu, Finland

    Ylermi Soini

  3. Department of Pathology and Forensic Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, School of Medicine, Cancer Center of Eastern Finland, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland

    Ylermi Soini

Authors
  1. Simi Santala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Talvensaari-Mattila
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ylermi Soini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Markku Santala
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markku Santala.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Santala, S., Talvensaari-Mattila, A., Soini, Y. et al. Prognostic value of cyclin B in endometrial endometrioid adenocarcinoma. Tumor Biol. 36, 953–957 (2015). https://doi.org/10.1007/s13277-014-2676-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2676-4

Keywords

Search

Navigation